Nodi Dehvari

Stockholm, AB, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity.

GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity.

Journal: Cell

Published: August 29, 2025

GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity.

GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity.

Journal: Cell

Published: June 28, 2024

The novel adrenergic agonist ATR-127 targets skeletal muscle and brown adipose tissue to tackle diabesity and steatohepatitis.

The novel adrenergic agonist ATR-127 targets skeletal muscle and brown adipose tissue to tackle diabesity and steatohepatitis.

Journal: Molecular metabolism

Published: January 12, 2024

The metabolic effects of mirabegron are mediated primarily by β3 -adrenoceptors.

The metabolic effects of mirabegron are mediated primarily by β3 -adrenoceptors.

Journal: Pharmacology research & perspectives

Published: June 16, 2020

Treatment with a β-2-adrenoceptor agonist stimulates glucose uptake in skeletal muscle and improves glucose homeostasis, insulin resistance and hepatic steatosis in mice with diet-induced obesity.

Treatment with a β-2-adrenoceptor agonist stimulates glucose uptake in skeletal muscle and improves glucose homeostasis, insulin resistance and hepatic steatosis in mice with diet-induced obesity.

Journal: Diabetologia

Published: January 17, 2020

BRL37344 stimulates GLUT4 translocation and glucose uptake in skeletal muscle via β2-adrenoceptors without causing classical receptor desensitization.

BRL37344 stimulates GLUT4 translocation and glucose uptake in skeletal muscle via β2-adrenoceptors without causing classical receptor desensitization.

Journal: American journal of physiology. Regulatory, integrative and comparative physiology

Published: March 21, 2019

Mirabegron: potential off target effects and uses beyond the bladder.

Mirabegron: potential off target effects and uses beyond the bladder.

Journal: British journal of pharmacology

Published: August 29, 2017

The PPARγ agonist rosiglitazone promotes the induction of brite adipocytes, increasing β-adrenoceptor-mediated mitochondrial function and glucose uptake.

The PPARγ agonist rosiglitazone promotes the induction of brite adipocytes, increasing β-adrenoceptor-mediated mitochondrial function and glucose uptake.

Journal: Cellular signalling

Published: May 30, 2017

β3-Adrenergically induced glucose uptake in brown adipose tissue is independent of UCP1 presence or activity: Mediation through the mTOR pathway.

β3-Adrenergically induced glucose uptake in brown adipose tissue is independent of UCP1 presence or activity: Mediation through the mTOR pathway.

Journal: Molecular metabolism

Published: January 20, 2017

Could burning fat start with a brite spark? Pharmacological and nutritional ways to promote thermogenesis.

Could burning fat start with a brite spark? Pharmacological and nutritional ways to promote thermogenesis.

Journal: Molecular nutrition & food research

Published: April 01, 2015

Response to Comment on Sato et al. Improving type 2 diabetes through a distinct adrenergic signaling pathway involving mTORC2 that mediates glucose uptake in skeletal muscle. Diabetes 2014;63:4115-4129.

Response to Comment on Sato et al. Improving type 2 diabetes through a distinct adrenergic signaling pathway involving mTORC2 that mediates glucose uptake in skeletal muscle. Diabetes 2014;63:4115-4129.

Journal: Diabetes

Published: November 22, 2014

Improving type 2 diabetes through a distinct adrenergic signaling pathway involving mTORC2 that mediates glucose uptake in skeletal muscle.

Improving type 2 diabetes through a distinct adrenergic signaling pathway involving mTORC2 that mediates glucose uptake in skeletal muscle.

Journal: Diabetes

Published: July 11, 2014

Showing 1-12 of 13

Last Updated: 09/26/2026